Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Engage Grants Program

Simon Fraser University

$24,419.00

Development of concurrent, dual-nucleus magnetic resonance imaging

EF 2014-15

Résumé
This project involves a partnership with Bruker, Ltd (Canada) to develop new technology for magneticresonance imaging (MRI). In the typical application of MRI, as used in medical facilities around the world, 2-Dand 3-D images of patients are generated by studying the environments of protons (1H). This technique hasproven invaluable for characterizing soft tissues such as those found in organs and tumors. To further extendthe application of MRI we propose to develop an innovative approach to tracking drugs inside patients. So thatthese compounds can be detected separately from their environments inside subjects of MRI imaging, we willuse fluorine (19F) containing compounds. This is particularly important for medical applications, since around25% of modern drugs contain fluorine. Furthermore, since fluorine is only found in trace amounts in biologicalsystems, 19F MRI measurements can readily and unequivocally map the distribution of fluorinated compounds.The technological development we propose is the concurrent MRI mapping of 1H and 19F. This approach hasseveral advantages: (i) rapid measurements, (ii) a single apparatus to measure both nuclei, (iii) accurate overlapof images from each nucleus, and (iv) allows time-dependent studies, particularly of drug diffusion. The teamof university researchers will contribute expertise in magnetic resonance imaging to optimize experimentalprotocols and assess limits on sensitivity and resolution. Furthermore, the university researchers will providechemical expertise for the preparation of fluorinated compounds, and biological techniques for growth ofcancer cells and tumor models, which will be the focus of proof-of-principle studies. Bruker will contributehands-on and remote assistance with programming and technical aspects along with software licenses for datacollection and analysis. With the development of this technology, Bruker will be in a position to commercialisethe new MRI instrumentation, and also produce marketable packages of pulse sequences, operating manualsand software.
Programme
Engage Grants Program
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data

Tel que publié

Application id
476514-2014
Name nom
Walsby, Charles
Department département
Chemistry
Organization id
5
Institution établissement
Simon Fraser University
Province en
British Columbia
Province fr
Colombie-Britannique
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2014
Competition year année de concours
2014
Award amount
24419
Program id
EGP
Program name en
Engage Grants Program
Program name fr
Programme de subventions d'engagement partenariat
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1554
Committee name en
Pacific Internal Decision Committee
Committee name fr
Comité de décision interne pour le Pacifique
Area of application code
518
Area of application group en
Manufacturing processes and products
Area of application group fr
Procédés et produits industriels
Area of application en
Medical equipment and apparatus
Area of application fr
Appareils et instruments médicaux
Research subject code
3505
Research subject group en
Analytical chemistry
Research subject group fr
Chimie analytique
Research subject en
Analytical spectroscopy
Research subject fr
Spectroscopie analytique
Partie
1
Nb partie
1
Application title
Development of concurrent, dual-nucleus magnetic resonance imaging
Keyword
NSERC
Application summary
This project involves a partnership with Bruker, Ltd (Canada) to develop new technology for magneticresonance imaging (MRI). In the typical application of MRI, as used in medical facilities around the world, 2-Dand 3-D images of patients are generated by studying the environments of protons (1H). This technique hasproven invaluable for characterizing soft tissues such as those found in organs and tumors. To further extendthe application of MRI we propose to develop an innovative approach to tracking drugs inside patients. So thatthese compounds can be detected separately from their environments inside subjects of MRI imaging, we willuse fluorine (19F) containing compounds. This is particularly important for medical applications, since around25% of modern drugs contain fluorine. Furthermore, since fluorine is only found in trace amounts in biologicalsystems, 19F MRI measurements can readily and unequivocally map the distribution of fluorinated compounds.The technological development we propose is the concurrent MRI mapping of 1H and 19F. This approach hasseveral advantages: (i) rapid measurements, (ii) a single apparatus to measure both nuclei, (iii) accurate overlapof images from each nucleus, and (iv) allows time-dependent studies, particularly of drug diffusion. The teamof university researchers will contribute expertise in magnetic resonance imaging to optimize experimentalprotocols and assess limits on sensitivity and resolution. Furthermore, the university researchers will providechemical expertise for the preparation of fluorinated compounds, and biological techniques for growth ofcancer cells and tumor models, which will be the focus of proof-of-principle studies. Bruker will contributehands-on and remote assistance with programming and technical aspects along with software licenses for datacollection and analysis. With the development of this technology, Bruker will be in a position to commercialisethe new MRI instrumentation, and also produce marketable packages of pulse sequences, operating manualsand software.